183 related articles for article (PubMed ID: 2626520)
1. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
[No Abstract] [Full Text] [Related]
5. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Midha KK
Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Hubbard JW; Midha KK
Ther Drug Monit; 1990 May; 12(3):268-76. PubMed ID: 2349611
[TBL] [Abstract][Full Text] [Related]
8. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
[TBL] [Abstract][Full Text] [Related]
9. Fluphenazine blood levels and clinical response.
Harris PQ; Friedman MJ; Cohen BM; Cooper TB
Biol Psychiatry; 1982 Oct; 17(10):1123-30. PubMed ID: 7171656
[TBL] [Abstract][Full Text] [Related]
10. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
Schooler NR; Levine J
Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
[TBL] [Abstract][Full Text] [Related]
11. Plasma fluphenazine levels measured by high-performance liquid chromatography in patients treated with depot injections.
Jouen F; Verité P; André D; Colonna L; Boucly P
Arzneimittelforschung; 1993 May; 43(5):509-11. PubMed ID: 8328993
[TBL] [Abstract][Full Text] [Related]
12. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
13. Clinical perspectives of some neuroleptics through development and application of their assays.
Midha KK; Marder SR; Jaworski TJ; McKay G; Hubbard JW; Hawes EM; Van Putten T; Wirshing WC; Aravagiri M
Ther Drug Monit; 1993 Jun; 15(3):179-89. PubMed ID: 8101398
[TBL] [Abstract][Full Text] [Related]
14. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
[TBL] [Abstract][Full Text] [Related]
15. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
[No Abstract] [Full Text] [Related]
17. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
Turbott J; Villiger J; Hunter L
Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
[TBL] [Abstract][Full Text] [Related]
18. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
[No Abstract] [Full Text] [Related]
19. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
[TBL] [Abstract][Full Text] [Related]
20. Fluphenazine plasma levels and clinical response.
Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
